News & Updates

Individuals who are overweight or obese can achieve an approximately 10 percent weight loss over 3–5 years with the use of anti-obesity medications in addition to lifestyle management, according to a retrospective study presented at ENDO 2022.

In the secondary analysis of the phase III ADVANCE trial, responder rates were markedly higher with atogepant irrespective of dose than with placebo in adults with migraine.

Chronic obstructive pulmonary disease (COPD) patients initiating treatment with a long-acting muscarinic antagonist (LAMA) plus a long-acting β2-agonist (LABA) tend to have higher disease severity than those who are started on LAMA, according to real-world data from Singapore. However, there are as many patients who experience clinical worsening in the LAMA group as there are in the LAMA+LABA group.

People who inject drugs (PWID) and are receiving treatment for hepatitis C virus (HCV) show a substantial decline in liver disease and mortality, according to a study.

Psoriatic arthritis (PsA) patients with moderate disease activity (MDA) at baseline who are treated with apremilast are more likely to achieve treatment targets than those with high disease activity (HDA), a recent study has shown.

There are currently 40 approved vaccines against COVID-19, of which 11 have been granted Emergency Use Authorization by the World Health Organization. [covid19.trackvaccines.org/vaccines/approved] With over 300 other candidates in the development pipeline – over 100 of which are in clinical testing [vac-lshtm.shinyapps.io/ncov_vaccine_landscape] – are new vaccines necessary?

Treatment with the combination of ribociclib plus binimetinib appears to be well tolerated and delivers modest clinical activity in patients with locally advanced or metastatic melanoma harbouring NRAS mutation, according to the results of a phase Ib/II study.

A novel nitric oxide-releasing gel, berdazimer 10.3%, proves effective in the treatment of patients with water warts or molluscum contagiosum skin infection, facilitating clearance of lesions with low adverse event rates, as shown in the phase III B-SIMPLE4 trial.